China grants EUA to Covid-19 vaccineCovid-19 vaccine against XBB descendent lineages
09 Jun 2023
VaccineEmergency Use AuthorizationDrug ApprovalClinical StudymRNA
Preview
Source: Pharmaceutical Technology
The vaccine demonstrated an excellent safety profile and 93.28% protective efficacy 14 days after injection. Credit: WestVac BioPharma Co., Ltd./ CNW.
WestVac Biopharma has announced that the Chinese authorities have granted emergency use authorisation (EUA) for coviccine trivalent XBB.1.5-recombinant Covid-19 trivalent (XBB.1.5+BA.5+delta) protein vaccine (Sf9 cell).
This marks the world’s first Covid-19 vaccineCovid-19 vaccine approved for emergency use against XBB descendent lineages of SARS-CoV-2.
Recommended Reports
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - influenza [strains A/H1N1 + A/H3N2 + B/Hong Kong] vaccine GlobalData
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - influenza [strain A/Singapore/INFIMH-16-0019/2016 (H3N2)] (monovalent) vacci... GlobalData
View all
The vaccine has been developed by WestVac Biopharma along with the West China Medical Center and Sichuan University.
WestVac Biopharma and its subsidiary WestVac Biopharma (Guangzhou) constructed the vector for the coviccine vaccine using the fast response of the insect cell expression platform.
The subunit antigen in the vaccine has been based on the structure of the targeting S-RBD and HR proteins of the XBB and BA.5 subvariants.
It is self-assembled into stable trimeric protein particles with the addition of squalene-based oil-in-water emulsion adjuvant following purification and mixing.
Trials demonstrated that the vaccine induced a high titer of neutralising antibodies against several subvariants, including Omicron subvariants XBB.1.5, XBB1.16, XBB1.9.1, XBB.2.3, BA.2.75, BQ.1, BA.5 and BF.7.
The vaccine demonstrated an excellent safety profile and 93.28% protective efficacy against XBB.1, XBB.1.5, and XBB1.9, 14 days after injection.
The results indicated that coviccine trivalent XBB.1.5 is a Covid-19 vaccineCovid-19 vaccine with a broad spectrum to tackle several prevalent subvariants in China and globally.
China’s authorities granted an EUA for WestVac Biopharma’s coviccine-recombinant Covid-19 vaccineCovid-19 vaccine (Sf9 cell) in December 2022.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.